ONO PHARMA USA's Generous Support for Conquer Cancer's Mission
June 27, 2024, 9:45 pm
Location: United States, Virginia, Alexandria
Employees: 11-50
Founded date: 1999
ONO PHARMA USA, a leading pharmaceutical company, has announced a significant sponsorship of $1 million to support Conquer Cancer, the ASCO Foundation. This partnership aims to advance cancer research and education, with a focus on accelerating breakthroughs in lifesaving research and empowering individuals worldwide to conquer cancer.
Conquer Cancer, a global community of advocates, patients, doctors, researchers, and caregivers, is dedicated to improving the lives of those affected by cancer. The organization's Mission Endowment, supported by ONO PHARMA USA's generous gift, provides a long-term base of support to advance critical missions in cancer care and treatment. This collaboration underscores ONO PHARMA USA's commitment to addressing unmet medical needs in oncology and making a positive impact on the global fight against cancer.
Kunihiko Ito, CEO and President of ONO PHARMA USA, emphasized the importance of partnering with stakeholders in the cancer community to accelerate breakthroughs in cancer research. The $1 million disbursement over the next four years will support Conquer Cancer's efforts in funding research, education, and support programs. To date, Conquer Cancer has raised over $500 million to fund clinical and translational cancer research, supporting physician-scientists at all stages of their careers.
David Trexler, Chief Commercial Officer at ONO PHARMA USA, highlighted the shared vision of improving lives by bringing effective cancer treatments to patients in need. The collaboration with Conquer Cancer and ASCO, the world's leading professional organization for oncology professionals, aims to enhance cancer care and address unmet medical needs globally.
Nancy Daly, CEO of Conquer Cancer, expressed gratitude for ONO PHARMA USA's multi-year support, emphasizing the impact it will have on patients worldwide. The partnership between the two organizations will help turn promising research ideas into lifesaving realities, benefiting every cancer patient.
ONO PHARMA USA, established in 1998 as the U.S. subsidiary of Ono Pharmaceutical Co., Ltd., is dedicated to the clinical development of new drug candidates and expanding operations in the U.S. The company's focus on oncology, immunology, neurology, and other specialty areas aligns with its commitment to creating innovative medicines.
Conquer Cancer, through its Grants & Awards program, has awarded over $190 million in funding to improve cancer care and accelerate breakthroughs in oncology research. The organization's donors support vital programs that deliver high-quality, equitable patient care and share a vision of a world where cancer is prevented or cured, and every survivor is healthy.
In conclusion, ONO PHARMA USA's support for Conquer Cancer underscores a shared commitment to advancing cancer research, education, and treatment. This partnership exemplifies the collective effort to conquer cancer and improve outcomes for patients worldwide.
Conquer Cancer, a global community of advocates, patients, doctors, researchers, and caregivers, is dedicated to improving the lives of those affected by cancer. The organization's Mission Endowment, supported by ONO PHARMA USA's generous gift, provides a long-term base of support to advance critical missions in cancer care and treatment. This collaboration underscores ONO PHARMA USA's commitment to addressing unmet medical needs in oncology and making a positive impact on the global fight against cancer.
Kunihiko Ito, CEO and President of ONO PHARMA USA, emphasized the importance of partnering with stakeholders in the cancer community to accelerate breakthroughs in cancer research. The $1 million disbursement over the next four years will support Conquer Cancer's efforts in funding research, education, and support programs. To date, Conquer Cancer has raised over $500 million to fund clinical and translational cancer research, supporting physician-scientists at all stages of their careers.
David Trexler, Chief Commercial Officer at ONO PHARMA USA, highlighted the shared vision of improving lives by bringing effective cancer treatments to patients in need. The collaboration with Conquer Cancer and ASCO, the world's leading professional organization for oncology professionals, aims to enhance cancer care and address unmet medical needs globally.
Nancy Daly, CEO of Conquer Cancer, expressed gratitude for ONO PHARMA USA's multi-year support, emphasizing the impact it will have on patients worldwide. The partnership between the two organizations will help turn promising research ideas into lifesaving realities, benefiting every cancer patient.
ONO PHARMA USA, established in 1998 as the U.S. subsidiary of Ono Pharmaceutical Co., Ltd., is dedicated to the clinical development of new drug candidates and expanding operations in the U.S. The company's focus on oncology, immunology, neurology, and other specialty areas aligns with its commitment to creating innovative medicines.
Conquer Cancer, through its Grants & Awards program, has awarded over $190 million in funding to improve cancer care and accelerate breakthroughs in oncology research. The organization's donors support vital programs that deliver high-quality, equitable patient care and share a vision of a world where cancer is prevented or cured, and every survivor is healthy.
In conclusion, ONO PHARMA USA's support for Conquer Cancer underscores a shared commitment to advancing cancer research, education, and treatment. This partnership exemplifies the collective effort to conquer cancer and improve outcomes for patients worldwide.